Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   18/04/2024
1,320 USD (-2,22%)
(-2,22%)   18/04/2024

Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm

NEW YORK, Dec. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ: NKTR) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

If you own NKTR please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com. There is no cost to you. Moore Kuehn is a New York-based law firm with attorneys representing investors and consumers.

Please visit http://www.moorekuehn.com/practice/new-york-shareholder-derivative-litigation/

Attorney advertising. Prior results do not guarantee similar outcomes.

Moore Kuehn, PLLC
Justin Kuehn, Esq.
30 Wall Street, 8th Floor
New York, New York 10005
jkuehn@moorekuehn.com 
(212) 709-8245

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/moore-kuehn-pllc-encourages-investors-of-nektar-therapeutics-to-contact-law-firm-301704343.html

SOURCE Moore Kuehn, PLLC

Mijn selecties